-
1
-
-
33845890326
-
Effects of continuing or stopping alendronate after 5 years of treatment-The Fracture Intervention Trial Long-term Extension (FLEX): A randomized trial
-
Black D.M., Schwartz A.V., Ensrud K.E., et al. Effects of continuing or stopping alendronate after 5 years of treatment-The Fracture Intervention Trial Long-term Extension (FLEX): A randomized trial. JAMA 296 (2006) 2927
-
(2006)
JAMA
, vol.296
, pp. 2927
-
-
Black, D.M.1
Schwartz, A.V.2
Ensrud, K.E.3
-
2
-
-
33845878280
-
Ten vs five years of bisphosphonate treatment for postmenopausal osteoporosis: Enough of a good thing
-
Colón-Emeric C.S. Ten vs five years of bisphosphonate treatment for postmenopausal osteoporosis: Enough of a good thing. JAMA 296 (2006) 2968
-
(2006)
JAMA
, vol.296
, pp. 2968
-
-
Colón-Emeric, C.S.1
-
3
-
-
0031977199
-
Nitrogen containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras
-
Luckman S.P., Hughes D.E., Coxon F.P., et al. Nitrogen containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 13 (1998) 581
-
(1998)
J Bone Miner Res
, vol.13
, pp. 581
-
-
Luckman, S.P.1
Hughes, D.E.2
Coxon, F.P.3
-
4
-
-
14644414818
-
Pharmacokinetic considerations in determining the terminal elimination half-lives of bisphosphonates
-
Lasseter K.C., Porras A.G., Denker A., et al. Pharmacokinetic considerations in determining the terminal elimination half-lives of bisphosphonates. Clin Drug Investig 25 (2005) 107
-
(2005)
Clin Drug Investig
, vol.25
, pp. 107
-
-
Lasseter, K.C.1
Porras, A.G.2
Denker, A.3
-
5
-
-
33847284113
-
American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws
-
Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons
-
Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 65 (2007) 369
-
(2007)
J Oral Maxillofac Surg
, vol.65
, pp. 369
-
-
-
6
-
-
32644455093
-
Jaw osteonecrosis associated with bisphosphonates: Multiple exposed areas and its relationship to teeth extractions. Study of 20 cases
-
Bagan J.V., Jimenez Y., Murillo J., et al. Jaw osteonecrosis associated with bisphosphonates: Multiple exposed areas and its relationship to teeth extractions. Study of 20 cases. Oral Oncol 42 (2006) 327
-
(2006)
Oral Oncol
, vol.42
, pp. 327
-
-
Bagan, J.V.1
Jimenez, Y.2
Murillo, J.3
-
7
-
-
33847173476
-
Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia
-
Mavrokokki T., Cheng A., Stein B., et al. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 65 (2007) 415
-
(2007)
J Oral Maxillofac Surg
, vol.65
, pp. 415
-
-
Mavrokokki, T.1
Cheng, A.2
Stein, B.3
-
8
-
-
41849148629
-
Use of oral bisphosphonates and the risk of aseptic osteonecrosis: A nested case-control study
-
Etminan M., Aminzadeh K., Matthew I.R., et al. Use of oral bisphosphonates and the risk of aseptic osteonecrosis: A nested case-control study. J Rheumatol 35 (2008) 3
-
(2008)
J Rheumatol
, vol.35
, pp. 3
-
-
Etminan, M.1
Aminzadeh, K.2
Matthew, I.R.3
|